soluble guanylyl cyclase
Summary: A mammalian enzyme composed of a heterodimer of alpha and beta subunits. Each subunit consists of four domains; N-terminal HNOX domain, PAS-like domain, a coiled-coil domain, and a C-terminal catalytic domain. All four domains are homologous proteins with a similar conformation of functional domains. Soluble guanylate cyclase catalyzes the formation of cyclic GMP from GTP, and is a key enzyme of the nitric oxide signaling pathway involved in the regulation of a variety of biological and physiological processes in mammals.
Yamashita A, Ancillotti M, Rangel L, Fontenele M, Figueiredo Freitas C, Possidonio A, et al
. Balance between S-nitrosylation and denitrosylation modulates myoblast proliferation independently of soluble guanylyl cyclase activation. Am J Physiol Cell Physiol. 2017;313:C11-C26 pubmed publisher
..without S-nitrosocysteine (CysNO), 8-Br-cGMP, DETA-NO, or inhibitors for NO synthase (NOS), GSNOR, soluble guanylyl cyclase (sGC), or a combination of these, followed by analysis of GSNOR activity, protein expression, RSNO, cGMP, ..
Navolotskaya E, Sadovnikov V, Zinchenko D, Zolotarev Y, Lipkin V, Zav yalov V. Interaction of Cholera Toxin B-subunit with Human T-lymphocytes. Biochemistry (Mosc). 2017;82:1036-1041 pubmed publisher
..The KKEKL peptide tested in parallel did not affect sGC activity. Thus, the CT-B and peptide LKEKK binding to a common receptor on the surface of T-lymphocytes leads to an increase in sGC activity...
Stasch J, Pacher P, Evgenov O. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263-73 pubmed publisher
Kessler T, Wobst J, Wolf B, Eckhold J, Vilne B, Hollstein R, et al
. Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus. Circulation. 2017;136:476-489 pubmed publisher
..The locus encompasses GUCY1A3, which encodes the ?1 subunit of the soluble guanylyl cyclase (sGC), a key enzyme in the nitric oxide/cGMP signaling pathway...
Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, et al
. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem. 2017;60:5146-5161 pubmed publisher
..These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported. ..
Huang C, Alapa M, Shu P, Nagarajan N, Wu C, Sadoshima J, et al
. Guanylyl cyclase sensitivity to nitric oxide is protected by a thiol oxidation-driven interaction with thioredoxin-1. J Biol Chem. 2017;292:14362-14370 pubmed publisher
..The etiology of some oxidative vascular diseases may very well be explained by the dysfunction of the Trx1-GC1 association. ..
Zhou J, Gao S, Hsieh C, Malla M, Shemshedini L. Peptide B targets soluble guanylyl cyclase ?1 and kills prostate cancer cells. PLoS ONE. 2017;12:e0184088 pubmed publisher
Among androgen-regulated genes, soluble guanylyl cyclase ?1 (sGC?1) is significant in promoting the survival and growth of prostate cancer cells and does so independent of nitric oxide (NO) signaling...
Klinger J, Kadowitz P. The Nitric Oxide Pathway in Pulmonary Vascular Disease. Am J Cardiol. 2017;120:S71-S79 pubmed publisher
..cells by nitric oxide synthase and diffuses to adjacent vascular smooth muscle cells where it activates soluble guanylyl cyclase. This enzyme converts GTP to cGMP which activates cGMP dependent protein kinase leading to a series of ..
McMahon T, Bryan N. Biomarkers in Pulmonary Vascular Disease: Gauging Response to Therapy. Am J Cardiol. 2017;120:S89-S95 pubmed publisher